The application of this technology will not be limited to AML, where MPO-mediated ROS response can be used as a prognostic measure, but also in other cancers where tumor-associated neutrophils suppress T cell immunity via generation of ROS response [4, 44]. This evidence concerns the gene MPO and neoplasm.